1. Home
  2. IMMP vs CATO Comparison

IMMP vs CATO Comparison

Compare IMMP & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.38

Market Cap

61.4M

Sector

Health Care

ML Signal

HOLD

Logo Cato Corporation (The)

CATO

Cato Corporation (The)

HOLD

Current Price

$3.42

Market Cap

58.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMP
CATO
Founded
1987
1946
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Clothing/Shoe/Accessory Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
61.4M
58.0M
IPO Year
2012
1994

Fundamental Metrics

Financial Performance
Metric
IMMP
CATO
Price
$0.38
$3.42
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$5.50
N/A
AVG Volume (30 Days)
279.9K
120.3K
Earning Date
05-12-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
68.04
EPS
N/A
0.47
Revenue
N/A
$653,812,000.00
Revenue This Year
$445.09
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$7.09
Revenue Growth
N/A
0.62
52 Week Low
$0.29
$2.59
52 Week High
$3.53
$4.92

Technical Indicators

Market Signals
Indicator
IMMP
CATO
Relative Strength Index (RSI) 39.53 54.16
Support Level $0.35 $2.81
Resistance Level $0.39 $3.61
Average True Range (ATR) 0.02 0.18
MACD -0.00 0.00
Stochastic Oscillator 12.44 72.22

Price Performance

Historical Comparison
IMMP
CATO

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

About CATO Cato Corporation (The)

The Cato Corp seeks to offer quality fashion apparel and accessories at low prices every day, in junior/missy and plus sizes. The Cato concept's stores and e-commerce website feature a broad assortment of apparel and accessories, including dressy, career, and casual sportswear, dresses, coats, shoes, lingerie, costume jewelry, and handbags. Management believes the Company's success is dependent upon its ability to differentiate its stores from department stores, mass merchandise discount stores, and competing specialty stores. The key elements of the Company's business are: Merchandise Assortment, Value Pricing, Strip Shopping Center Location, Customer Service, Credit and Layaway Programs.

Share on Social Networks: